New research indicates that individuals who come off new slimming jabs like semaglutide or tirzepatide may regain lost weight far faster than those who stop conventional lifestyle programs.
Findings released in a major health publication shows that while obese individuals often shed a large proportion of their total mass while on the medication, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing such medications must be cognizant of the potential of rapid weight regain when the treatment ends," warns expert Dr. Susan Jebb.
This pace of recovery suggests a return to starting weight within about a year and a half.
Comparing Approaches
The study, which reviewed dozens of trials involving thousands of participants, compared the results of the injectable medications with other pills.
The team point out that people who shed pounds through lifestyle changes alone usually see a slower weight regain—perhaps 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Doctors propose the way of the drugs explains the amplified rebound.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of the hormone concentrations far above than the body's typical production might result in the body to produce less of its own natural GLP-1, and could lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication results in appetite is unsuppressed, making excessive eating far more likely."
A Lifelong Disease?
Medical guidelines advise the injections for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians say that, considering the likelihood of relapse, the therapy should be considered life-long.
This perspective is supported by pharmaceutical companies, who note that the results "highlight the chronic character of obesity," comparing it to managing conditions like diabetes.
User Accounts
People who have stopped the medication describe a intense return of hunger.
"It felt as if something that goes on and you become starving," said one woman.
The struggle is compounded if individuals have not developed lasting dietary or behavioural modifications during treatment.
Widespread Use
Figures indicate that millions of adults in the UK have used these injections in the last 12 months, with demand remaining high.
- Use is higher among women compared to men.
- The middle-aged age group shows the highest usage rates.
- Many access the medications through private healthcare rather than public health services.
Finally, experts caution that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent solution and lasting health benefits relies on ongoing behavioural management.
